Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children: A randomized, placebo-controlled trial.

ABSTRACT:

Background

Prior studies of peanut sublingual immunotherapy (SLIT) have suggested a potential advantage with younger age at treatment initiation.

Objective

We studied the safety and efficacy of SLIT for peanut allergy in 1- to 4-year-old children.

Methods

Peanut-allergic 1- to 4-year-old children were randomized to receive 4 mg peanut SLIT versus placebo. Desensitization was assessed by double-blind, placebo-controlled food challenge (DBPCFC) after 36 months of treatment. Participants desensitized to at least 443 mg peanut protein discontinued therapy for 3 months and then underwent DBPCFC to assess for remission. Biomarkers were measured at baseline and longitudinally during treatment.

Results

Fifty participants (25 peanut SLIT, 25 placebo) with a median age o

SUBMITTER: Kim EH 

PROVIDER: S-EPMC10872748 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature